AI’s Impact on Elections: New Policy Paper Highlights Urgent Global Challenge
24.1.2025 13:01:00 CET | Business Wire | Press release
Artificial intelligence (AI) is transforming political campaigns worldwide, creating unprecedented opportunities while amplifying risks for democratic processes. According to the newly launched policy paper, The Pervasive Influence of AI on Global Political Campaigns 2024, AI-driven techniques, such as generative AI (genAI), have revolutionized voter engagement through personalized messaging. However, genAI has also emerged as a double-edged sword: while enabling effective campaigning, it has been a significant source of disinformation, eroding trust in democratic institutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122148789/en/

Future Shift Labs Co-founder Sagar Vishnoi addresses IPE25 in Cape Town (Photo: Business Wire)
For instance, the United States, classified as “severely polarized” and ranked 3rd among 28 countries for polarization, illustrates how AI-generated propaganda exacerbates societal divisions. Further, the U.S. ranks 1st in distrust of social media, exposing vulnerabilities to AI-driven disinformation campaigns. Russia’s Foreign Influence and Malign Interference (FIMI) activities have prominently leveraged AI tools to spread targeted propaganda. Generative AI platforms like "Doppelganger" have repeatedly been used to sow disinformation and undermine public trust globally. The study underscores the urgent need for governments to regulate AI in elections to prevent future misuse and safeguard democratic integrity.
The policy paper, authored by Alisha Butala, Dr. Christopher Nehring, and Mateusz Łabuz, was developed by Future Shift Labs, a global think tank exploring AI and governance. Officially unveiled on the 23rd of January at the IPE Campaign Expo 2025 in Cape Town, South Africa, the paper provides actionable insights and global case studies. It emphasizes the importance of clear regulations, ethical standards, and investment in public education to combat AI-enabled electoral interference.
Nitin Narang, Founder of Future Shift labs who played a pivotal role in bringing this project to fruition, remarked: "At its core, this research is about people - voters, citizens, and communities. Our team's work is driven by a shared commitment to understanding how AI is reshaping our democratic landscape. By shedding light on these critical issues, we hope to contribute to a more informed, inclusive, and resilient global conversation."
Dr. Israel Govender, a thought leader in technology governance, added: “As we reflect on AI's rapid evolution, our choices today will shape the future of democracy. This research provides a critical perspective on the impact of technology on our values and institutions, serving as a valuable resource for responsible innovation.”
Sagar Vishnoi, Co-founder of Future Shift Labs, and Glen Mpani, organizer of IPE 2025, were present at the launch, reinforcing the think tank's commitment to fostering global discussions on AI governance, transparency, and accountability. Vishnoi notes "Blockchain technology will become the base for other applications in political campaigns, blending seamlessly into the ecosystem, much like AI's current role."
Future Shift Labs is an emerging global think tank dedicated to advancing AI policies and integrating digital statecraft with cutting-edge technologies. The IPE Campaign Expo 2025, renowned for showcasing political innovations, and Kairos Communications, as the principal partner, provided the perfect platform for this milestone launch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122148789/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom